@hitesh2710 - A quick question - Has Shilpa received EIR for the formulation facility? Think only inspection is through. Please clarify if my understanding is incorrect.
Shilpa's BSE notification dated 26-Jul:
"Shilpa Medicare Ltd has informed BSE that the Company had an audit conducted by the United States Food & Drug Administration (USFDA) at the SEZ Formulations facility situated at Jadcherla, near Hyderabad, from July 18, 2016 to July 26, 2016.
The Company has received without 483 for the above mentioned facility."
Also I saw a brokerage note saying they had a planned shutdown in Q1 for expansion of formulation facility. Possibly one of the reasons for muted qtr.
Disc - Long, no trades in many months.